BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $51 from $52 and keeps a Buy rating on the shares. The firm notes that Agios announced an extension of its PDUFA date from September 7th to December 7th, 2025 following the submission of a REMS for hepatocellular injury. The company noted that the extension was not the result of new data requested by the FDA or submitted by the company. BofA still views approval in thalassemia as likely given its key opinion leader checks and the strength of data from both ENERGIZE and ENERGIZE-T trials. As such, Agios remains one of the firm’s top picks even with the delay.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals falls -14.4%
- Agios Pharmaceuticals provides update on U.S. PDUFA goal date for PYRUKYND
- Positive Outlook for Agios Pharma Despite Recent Patient Deaths Unrelated to Pyrukynd Treatment
- Agios Pharmaceuticals reports Pyrukynd approval by Saudi Food and Drug Authority
- Agios Pharma’s PYRUKYND Approved by Saudi Authority